hydroxyproline has been researched along with Osteolysis in 17 studies
Hydroxyproline: A hydroxylated form of the imino acid proline. A deficiency in ASCORBIC ACID can result in impaired hydroxyproline formation.
hydroxyproline : A proline derivative that is proline substituted by at least one hydroxy group.
Osteolysis: Dissolution of bone that particularly involves the removal or loss of calcium.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 9.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 9.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| "The simple postabsorptive urine hydroxyproline (Spot-HYPRO) with dialyzable and non-dialyzable (ND) fractions was measured in 28 patients with multiple myeloma." | 7.66 | The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma. ( Neely, CL; Niell, HB; Palmieri, GM, 1981) |
| "Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease." | 5.27 | Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease. ( Bolzonella, S; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Paccagnella, A; Salvagno, L; Scalella, P, 1984) |
| " In 21 patients with breast cancer and TIO, we determined the biochemical effects of a single infusion of pamidronate given at 30 mg (n = 5), 60 mg (n = 5), 90 mg (n = 5), or 120 mg (n = 6)." | 5.08 | Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study. ( Body, JJ; Dumon, JC; Ford, J; Piccart, M, 1995) |
| "Pamidronate, an aminobisphosphonate, has been shown to lower the risk of skeletal complications associated with lytic bone lesions for up to 1 year in women with stage IV breast cancer who received chemotherapy." | 5.08 | Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. ( Blayney, D; Heffernan, M; Hortobagyi, GN; Knight, RD; Lipton, A; Mellars, K; Porter, L; Reitsma, DJ; Seaman, JJ; Simeone, JF; Sinoff, C; Theriault, RL; Wheeler, H, 1998) |
| " We compared several new markers of bone turnover in normocalcaemic patients with breast cancer-induced osteolysis before and after a single infusion of the bisphosphonate pamidronate." | 3.69 | Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy. ( Body, JJ; Delmas, PD; Dumon, JC; Gineyts, E, 1997) |
| "The simple postabsorptive urine hydroxyproline (Spot-HYPRO) with dialyzable and non-dialyzable (ND) fractions was measured in 28 patients with multiple myeloma." | 3.66 | The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma. ( Neely, CL; Niell, HB; Palmieri, GM, 1981) |
| "In 70 patients with stage III multiple myeloma (MM) the authors studied spontaneous and lipopolysaccharide-induced production of interleukin-1 (IL-1) and interleukin-6 (IL-6) by blood and bone marrow mononuclear cells, concentration of parathyroid hormone and vitamin D3 in the serum." | 1.29 | [The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction]. ( Golenkov, AK; Kliushnenkova, EN; Lutskaia, TD; Mitina, TA; Novikov, VE; Tishenina, RS; Valiulina, LS, 1996) |
| "Our data indicate that HOP in multiple myeloma at diagnosis is closely related to the extension of skeletal lesions and that during the clinical course it may be useful in the follow-up of bone disease." | 1.27 | Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease. ( Bolzonella, S; Chiarion Sileni, V; De Besi, P; Fiorentino, MV; Paccagnella, A; Salvagno, L; Scalella, P, 1984) |
| "Rapid bone loss, high bone resorption and low calcium absorption are shown to be associated with poor oestrogen status, with crush fracture cases presenting an exaggerated view of the normal post-menopausal situation." | 1.26 | The relationship between oestrogen status and bone loss in post-menopausal women. ( Brook, R; Horsman, A; Nordin, BE; Williams, DA, 1976) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (64.71) | 18.7374 |
| 1990's | 5 (29.41) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| LAGIER, R | 1 |
| RUTISHAUSER, E | 1 |
| Karachalios, T | 1 |
| Lyritis, GP | 1 |
| Kaloudis, J | 1 |
| Roidis, N | 1 |
| Katsiri, M | 1 |
| Dady, PJ | 1 |
| Coombes, RC | 1 |
| Smith, IE | 1 |
| Parsons, CA | 1 |
| Ford, HT | 1 |
| Gazet, JC | 1 |
| Henk, JM | 1 |
| Nash, AG | 1 |
| Powles, TJ | 1 |
| Neuwirtová, R | 1 |
| Stĕpán, J | 1 |
| Pacovský, V | 1 |
| Formánková, J | 1 |
| Jarolímková, E | 1 |
| Bolzonella, S | 1 |
| Paccagnella, A | 1 |
| Salvagno, L | 1 |
| Chiarion Sileni, V | 1 |
| De Besi, P | 1 |
| Scalella, P | 1 |
| Fiorentino, MV | 1 |
| Niell, HB | 1 |
| Neely, CL | 1 |
| Palmieri, GM | 1 |
| O'Rourke, N | 1 |
| McCloskey, E | 1 |
| Houghton, F | 1 |
| Huss, H | 1 |
| Kanis, JA | 1 |
| Body, JJ | 3 |
| Dumon, JC | 2 |
| Piccart, M | 1 |
| Ford, J | 1 |
| Golenkov, AK | 1 |
| Lutskaia, TD | 1 |
| Kliushnenkova, EN | 1 |
| Tishenina, RS | 1 |
| Valiulina, LS | 1 |
| Novikov, VE | 1 |
| Mitina, TA | 1 |
| Gineyts, E | 1 |
| Delmas, PD | 1 |
| Hortobagyi, GN | 1 |
| Theriault, RL | 1 |
| Lipton, A | 1 |
| Porter, L | 1 |
| Blayney, D | 1 |
| Sinoff, C | 1 |
| Wheeler, H | 1 |
| Simeone, JF | 1 |
| Seaman, JJ | 1 |
| Knight, RD | 1 |
| Heffernan, M | 1 |
| Mellars, K | 1 |
| Reitsma, DJ | 1 |
| van Breukelen, FJ | 1 |
| Bijvoet, OL | 2 |
| van Oosterom, AT | 1 |
| Nordin, BE | 1 |
| Horsman, A | 1 |
| Brook, R | 1 |
| Williams, DA | 1 |
| Jayson, MI | 1 |
| Bailey, AJ | 1 |
| Black, C | 1 |
| Jones, KL | 1 |
| Borkowski, A | 1 |
| Cleeren, A | 1 |
| Kawamura, J | 1 |
| Tochigi, H | 1 |
| Yanagawa, M | 1 |
| Yoshida, O | 1 |
| Hida, S | 1 |
| Mori, O | 1 |
| Suzuki, N | 1 |
| Saito, K | 1 |
| Komatsu, Y | 1 |
| Hatayama, T | 1 |
| Coleman, RE | 1 |
| Rubens, RD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Pilot Trial to Study the Safety and Efficacy of Concomitant Radiotherapy and Zoledronic Acid for the Palliation of Bone Metastases From Breast Cancer, Prostate Cancer and Lung Cancer[NCT00264420] | Phase 1 | 4 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 trials available for hydroxyproline and Osteolysis
| Article | Year |
|---|---|
The effects of calcitonin on acute bone loss after pertrochanteric fractures. A prospective, randomised trial.
Topics: Acute Disease; Administration, Intranasal; Aged; Aged, 80 and over; Alkaline Phosphatase; Biomarkers | 2004 |
Double-blind, placebo-controlled, dose-response trial of oral clodronate in patients with bone metastases.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neo | 1995 |
Intravenous pamidronate in patients with tumor-induced osteolysis: a biochemical dose-response study.
Topics: Adult; Aged; Analysis of Variance; Bone Neoplasms; Bone Resorption; Breast Neoplasms; Calcitriol; Ca | 1995 |
Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.
Topics: Alkaline Phosphatase; Analgesics; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; | 1998 |
13 other studies available for hydroxyproline and Osteolysis
| Article | Year |
|---|---|
OSTEOARTICULAR CHANGES IN A CASE OF ESSENTIAL OSTEOLYSIS; AN ANATOMICAL AND RADIOLOGICAL STUDY.
Topics: Adolescent; Blood; Bone Diseases; Bone Resorption; Cartilage Diseases; Elbow; Foot; Hand; Humans; Hy | 1965 |
Use of an antiosteolytic agent in treatment of patients with bone metastases from breast cancer.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Doxorubicin; Drug Therapy, Combination; Fema | 1980 |
[Biochemical monitoring of bone involvement in multiple myeloma].
Topics: Alkaline Phosphatase; Bone Resorption; Humans; Hydroxyproline; Multiple Myeloma; Osteolysis | 1983 |
Urinary hydroxyproline in multiple myeloma: correlation with clinical stages and bone disease.
Topics: Adult; Aged; Bone Diseases; Female; Fractures, Bone; Humans; Hydroxyproline; Male; Middle Aged; Mult | 1984 |
The postabsorptive urinary hydroxyproline (spot-HYPRO) in patients with multiple myeloma.
Topics: Bone Resorption; Creatinine; Dialysis; Follow-Up Studies; Humans; Hydroxyproline; Kidney Diseases; M | 1981 |
[The extratumor mechanisms of osteolysis in multiple myeloma and the means for their correction].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Density; Bone Marrow; Cholecalcife | 1996 |
Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Topics: Adult; Aged; Amino Acids; Analysis of Variance; Biomarkers; Bone Neoplasms; Bone Resorption; Breast | 1997 |
Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Topics: Bone Resorption; Breast Neoplasms; Calcium; Creatinine; Diphosphonates; Female; Humans; Hydroxyproli | 1979 |
The relationship between oestrogen status and bone loss in post-menopausal women.
Topics: Aging; Bone Resorption; Calcium; Creatinine; Estrogens; Female; Fractures, Bone; Humans; Hydroxyprol | 1976 |
Collagen studies in acro-osteolysis.
Topics: Adult; Biopsy; Bone Resorption; Collagen; Fingers; Humans; Hydroxyproline; Male; Osteolysis; Proline | 1976 |
Treatment of malignancy-associated hypercalcemia with intravenous aminohydroxypropylidene diphosphonate.
Topics: Adult; Aged; Bone Neoplasms; Breast Neoplasms; Calcium; Cyclic AMP; Diphosphonates; Female; Head and | 1986 |
[Effects of etidronate disodium (EHDP) on urogenital malignancies with bone metastasis: a multicentered collaborative evaluation].
Topics: Aged; Aged, 80 and over; Alkaline Phosphatase; Bone and Bones; Bone Neoplasms; Calcium; Drug Evaluat | 1988 |
3(Amino-1,1-hydroxypropylidene) bisphosphonate (APD) for hypercalcaemia of breast cancer.
Topics: Adult; Aged; Breast Neoplasms; Calcium; Diphosphonates; Female; Fluid Therapy; Humans; Hydroxyprolin | 1987 |